HMNC Brain Health plans Phase 3 for ex-Sanofi depression drug despite mid-stage miss

HMNC Brain Health’s drug has missed the primary endpoint in a Phase 2b depression study designed to show efficacy in a genetically-defined patient subgroup. But the German biotech said its candidate, called BH-200, achieved positive ...